finder.com

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Intellipharmaceutics International stock

Own Intellipharmaceutics International stock in just a few minutes.

Buy Intellipharmaceutics International (IPCI)
Avatar
Jing Jun Ma
Fact checked

Intellipharmaceutics International Inc is an other business based in the US. Intellipharmaceutics International shares (IPCI) are listed on the NASDAQ and all prices are listed in US Dollars. Intellipharmaceutics International employs 59 staff.

How to buy shares in Intellipharmaceutics International

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IPCI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

What's in this guide?

  1. IPCI shares summary
  2. Compare share dealing platforms
  3. Is IPCI stock a buy or sell?
  4. Stock performance over time
  5. Intellipharmaceutics International's financials
  6. Does Intellipharmaceutics International pay a dividend?
  7. Other common questions

Intellipharmaceutics International share price

Use our graph to track the performance of IPCI stocks over time.

Intellipharmaceutics International shares at a glance

Information last updated 2021-01-22.
52-week range$0.12 - $0.22
50-day moving average $0.00
Wall St. target price$27.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Intellipharmaceutics International shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Go to site
More Info
Robinhood
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Go to site
More Info
Interactive Brokers
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Go to site
More Info
Webull
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Go to site
More Info
Public
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
Go to site
More Info
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Intellipharmaceutics International stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Intellipharmaceutics International Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Intellipharmaceutics International financials

Gross profit TTM $0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation $0

TTM: trailing 12 months

Intellipharmaceutics International share dividends

We're not expecting Intellipharmaceutics International to pay a dividend over the next 12 months.

Intellipharmaceutics International overview

IntelliPharmaCeutics International Inc. , a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Oxycodone ER, an abuse deterrent oxycodone hydrochloride extended release tablets; Regabatin and Lyrica pregabalin extended-release capsules for the management of neuropathic pain; Effexor XR, an extended-release capsule for oral administration to treat depression; Protonix, a delayed-release capsule for oral administration to treat gastroesophageal reflux disease; and Glucophage XR, a drug that treats type 2 diabetes. It also provides Seroquel XR, an oral psychotropic agent for the treatment of schizophrenia, bipolar disorder, and major depressive disorder; Lamictal XR, an anticonvulsant drug to terat epilepsy; Keppra XR, an antiepileptic drug for the treatment of partial onset seizures in patients with epilepsy; Pristiq, a selective serotonin and norepinephrine reuptake inhibitor to treat major depressive disorder; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company provides Focalin XR, an extended-release capsule for hyperactivity disorder. It has has a license and commercialization agreement with Par Pharmaceutical Inc.

  1. Technical analysis graphic from TradingView, https://uk.tradingview.com Stock prices and other date from EOD Historical Data

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site